PSORIASIS - OXYMED HYPERBARIC OXYGEN THERAPY TIER 2
Hyperbaric oxygen (HBO2) treatment is defined as breathing pure (100%) oxygen under conditions of increased atmospheric pressure. This results in elevated arterial oxygen tension to 2,000 mmHg or greater, which provides tissues with abundant oxygen. Possible complications of HBO2 therapy include barotrauma, oxygen toxicity (affecting the central nervous system and lungs), claustrophobia and anxiety, and ocular effects such as myopia and cataract.
HBO2 promotes proliferation of fibroblasts, epithelial cells, and blood vessels in a wound. It can increase the killing ability of leukocytes and is lethal to certain anaerobic bacteria. Furthermore, it inhibits toxin formation by certain anaerobes, increases the flexibility of red cells, reduces tissue edema, and conserves intracellular ATP.
The Undersea and Hyperbaric Medical Society and the Federal Center for Medicare and Medicaid Services have approved the use of HBO2 in 14 indications including gas gangrene, necrotizing soft-tissue infections, diabetic foot ulcer, compromised grafts and flaps, bone infection, intracranial abscess, anemia and blood loss, crush injury, carbon monoxide and cyanide poisoning, radiation complications, decompression sickness, and gas embolism.
HBO2 has potential effects on mediators of inflammation and the immune response. Our recent reviews [8,9] support the contention that HBO2 has anti-inflammatory and immunosuppressive properties. These properties make this treatment a potentially useful intervention that should be tested in the management of psoriasis and psoriatic arthritis.
J Med Case Reports. 2009; 3: 7023.
Published online 2009 Aug 10. doi: 10.1186/1752-1947-0003-0000007023
Therapeutic effect of hyperbaric oxygen in psoriasis vulgaris: two case reports and a review of the literature
Glenn Butler,1 Julio Chávarri Michaels,5 Noori Al-Waili,1,2 Michael Finkelstein,3 Michael Allen,1 Richard Petrillo,2 Zev Carrey,2 Bangaruraju Kolanuvada,2 Bok Y Lee,1,4 Alfonso Gonzales Riera,5 Cesar Chávarri Michaels,5 and Gary Urteaga6
Psoriasis is an inflammatory and immunological cutaneous disease. The high morbidity in patients with psoriasis results from severe clinical manifestations and/or adverse effects of treatment. The Undersea and Hyperbaric Medical Society and Federal Medicare and Medicaid Services have approved the use of hyperbaric oxygen (HBO2) for more than 15 indications, including wound healing, infections and late effects of radiation, which are largely unresponsive to conventional treatments. Accumulated data show that HBO2 has anti-inflammatory effects and other positive influences on the immune system, making it a rational treatment in the management of psoriasis plaques and arthritis.
We present the cases of two patients with long histories of psoriasis vulgarus who exhibited marked improvement with use of HBO2. The first patient was 40 years old and had pustular psoriasis and psoriatic arthritis. He was treated with six sessions of HBO2 (at 2.8 atmospheres of pressure for 60 minutes), which successfully controlled his symptoms. At the 18-month post-treatment follow up, the patient exhibited complete remission of psoriasis and marked improvement in psoriatic arthritis without medication.
The second patient was 55 years old with extensive psoriatic lesions, and exhibited marked improvement within 15 sessions of HBO2. No adverse effects of HBO2 were identified.
HBO2 may possess potential therapeutic efficacy in the management of psoriasis. We outline the pathogenesis of psoriasis and the selective anti-inflammatory and immunosuppressive effects of HBO2. We hope that this will provide a basis for elucidating the mechanisms of action and consequently pave the way for further controlled studies.
The results presented here demonstrate the effectiveness of HBO2 in alleviating signs and symptoms of psoriasis in two patients. No adverse effects were reported during or after treatment with HBO2.
Leukocytes, cytokines, and keratinocyte growth or differentiation abnormalities are involved in psoriatic skin lesions. Psoriasis vulgaris is a T-cell-driven disease, with type I (interferon-γ-producing) T cells predominating in skin lesions [10,11]. A lymphocytic infiltrate in psoriasis plaques consists of a mixture of activated CD4+ and CD8+ T cells; the latter predominate in lesional epidermis and CD4+ cells in the dermis . The therapeutic benefit of immunosuppressive drugs supports the view that activated T cells are pathogenic effectors of psoriasis . Dendritic cells are found in psoriatic skin lesions, producing interleukin (IL)-12 and IL-23.
Cytokine changes in psoriatic lesions consist of elevated levels of interferon-γ, tumor necrosis factor (TNF)-α, numerous interleukins (such as IL-1, IL-2, IL-6, IL-8, IL-12, IL-17, and IL-19), and multiple chemokines (MIG/CXCL9, IP-10/CXCL10, I-TAC/CXCL11, and MIP3α/CCL20) . IL-12 p40 mRNA and expression of interferon-γ, inducible nitric oxide synthase, B7-1, and TNF-α are elevated in psoriatic tissue .
A rheumatoid-like pattern has been identified as one of the most common types of psoriatic arthritis. Autoantibodies directed against nuclear antigens, cytokeratins, epidermal keratins, and heat shock proteins have also been reported in psoriatic arthritis.
HBO2 suppresses the proliferation of macrophages and the formation of foam cells in atherosclerotic lesions .
HBO2 also intensifies the suppressive function of T lymphocytes, normalizes cell-bound immunity, and decreases the serum concentration in immune complexes .
The immunosuppressive effects of HBO2 include suppression of autoimmune symptoms, decreased production of IL-1 and CD4+cells, and increased percentage and absolute number of CD8+ cells .
In addition, long-term HBO2 exposure suppresses development of autoimmune symptoms such as proteinuria, facial erythema, and lymphadenopathy.
HBO2 decreases the CD4:CD8 ratio and proliferation of lymphocytes, and activates neutrophils to migrate to regions of high oxygen tension .
HBO2 suppresses TNF-α production induced by lipopolysaccharide, lipid A, and phytohemagglutinin A . A marked decrease in IL-1 and IL-2 production, and a significant decrease in prostaglandin E2 production have been observed.
The positive clinical effects that HBO2 has in the treatment of chronic inflammation may relate to its effects on secretion of IL-1, IL-6, and TNF-α.
The effects of HBO2 on prostaglandin, nitric oxide, and cytokines involved in wound pathophysiology and inflammation in particular were recently reviewed .
That review indicates that HBO2 has important effects on the biology of cytokines and other mediators of inflammation.
HBO2 causes downregulation of cytokines and upregulation of growth factors.
It transiently suppresses stimulus-induced proinflammatory cytokine production and affects the liberation of TNF-α and endothelins.
Vascular endothelial growth factor levels are significantly increased with HBO2 therapy, whereas levels of prostaglandin E2 and cyclo-oxygenase-2 mRNA are markedly reduced.
Therefore, the anti-inflammatory and immunosuppressive properties of HBO2 might account for its efficacy in the cases presented here.